Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cardiff Oncology (CRDF) Cash from Operations (2016 - 2025)

Cardiff Oncology's Cash from Operations history spans 15 years, with the latest figure at 5967000.0 for Q4 2025.

  • For Q4 2025, Cash from Operations rose 41.88% year-over-year to 5967000.0; the TTM value through Dec 2025 reached 37923000.0, down 0.61%, while the annual FY2025 figure was 37923000.0, 0.61% down from the prior year.
  • Cash from Operations for Q4 2025 was 5967000.0 at Cardiff Oncology, up from 10834000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 4301000.0 in Q2 2021 and bottomed at 12794000.0 in Q1 2025.
  • The 5-year median for Cash from Operations is 7848500.0 (2023), against an average of 8168150.0.
  • The largest annual shift saw Cash from Operations crashed 74.39% in 2021 before it surged 41.88% in 2025.
  • A 5-year view of Cash from Operations shows it stood at 7390000.0 in 2021, then dropped by 27.06% to 9390000.0 in 2022, then rose by 23.97% to 7139000.0 in 2023, then crashed by 43.82% to 10267000.0 in 2024, then soared by 41.88% to 5967000.0 in 2025.
  • Per Business Quant, the three most recent readings for CRDF's Cash from Operations are 5967000.0 (Q4 2025), 10834000.0 (Q3 2025), and 8328000.0 (Q2 2025).